Prostaglandin analogs in ophthalmology.
Indian J Ophthalmol
; 71(5): 1768-1776, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-37203029
ABSTRACT
Glaucoma is a major cause of irreversible blindness worldwide. Reducing intraocular pressure (IOP) is currently the only approach to prevent further optic nerve head damage. Pharmacotherapy is the mainstay of treatment for glaucoma patients. In recent years, a significant milestone in glaucoma treatment has been a transition to prostaglandin analogs (PGAs) as the first line of drugs. The rapid shift from traditional ß-blockers to PGAs is primarily due to their excellent efficacy, convenient once-a-day usage, better diurnal control of IOP, and systemic safety profiles. This review article aims to provide information regarding the various PGAs in practice and also the newer promising drugs.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oftalmologia
/
Prostaglandinas F Sintéticas
/
Glaucoma
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article